Literature DB >> 16428746

Stimulation of CD8+ T cells following diphtheria toxin-mediated antigen delivery into dendritic cells.

Christine A Shaw1, Michael N Starnbach.   

Abstract

Recognition and clearance of many intracellular pathogens requires the activation and subsequent effector functions of CD8+ T lymphocytes. To stimulate CD8+ T cells by immunization, the target antigens must be delivered into the cytosol of host cells. There they can be processed into peptides and presented in the context of major histocompatibility complex class I molecules to antigen-specific CD8+ T cells. One method of delivering antigens into the cytosol is to fuse them to modified bacterial toxins that are able to enter mammalian cells. The expression pattern of the toxin receptors in the host will determine the cell population that the toxin fusion protein targets and will thus restrict antigen-specific T-cell recognition to the same population. In this study we describe the development and characterization of a diphtheria toxin (DT)-based antigen delivery system. Using CD11c-DTR transgenic mice that express the DT receptor in dendritic cells (DC), this system allows for targeted delivery of CD8+ T-cell antigen to DC. We show that antigen-specific CD8+ T cells proliferate in CD11c-DTR mice following immunization with catalytically inactive DT-antigen fusion proteins. We also show that a toxin-based system that restricts antigen delivery to DC results in more robust antigen-specific CD8+ T-cell proliferation than a toxin-based system that does not restrict delivery to a particular cell type. These results have implications for vaccine design, and they suggest that use of a toxin-based vector to target antigen to DC may be an effective way to induce a CD8+ T-cell response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16428746      PMCID: PMC1360329          DOI: 10.1128/IAI.74.2.1001-1008.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  47 in total

Review 1.  The control of T cell responses by dendritic cell subsets.

Authors:  S D Reid; G Penna; L Adorini
Journal:  Curr Opin Immunol       Date:  2000-02       Impact factor: 7.486

Review 2.  Antigen presentation and T cell stimulation by dendritic cells.

Authors:  Pierre Guermonprez; Jenny Valladeau; Laurence Zitvogel; Clotilde Théry; Sebastian Amigorena
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

3.  In vivo receptor-mediated delivery of a recombinant invasive bacterial toxoid to CD11c + CD8 alpha -CD11bhigh dendritic cells.

Authors:  Pierre Guermonprez; Catherine Fayolle; Marie-Jésus Rojas; Maria Rescigno; Daniel Ladant; Claude Leclerc
Journal:  Eur J Immunol       Date:  2002-11       Impact factor: 5.532

4.  In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens.

Authors:  Steffen Jung; Derya Unutmaz; Phillip Wong; Gen-Ichiro Sano; Kenia De los Santos; Tim Sparwasser; Shengji Wu; Sri Vuthoori; Kyung Ko; Fidel Zavala; Eric G Pamer; Dan R Littman; Richard A Lang
Journal:  Immunity       Date:  2002-08       Impact factor: 31.745

Review 5.  1st class ticket to class I: protein toxins as pathfinders for antigen presentation.

Authors:  Daniel C Smith; J Michael Lord; Lynne M Roberts; Eric Tartour; Ludger Johannes
Journal:  Traffic       Date:  2002-10       Impact factor: 6.215

6.  Diphtheria toxin receptor-mediated conditional and targeted cell ablation in transgenic mice.

Authors:  M Saito; T Iwawaki; C Taya; H Yonekawa; M Noda; Y Inui; E Mekada; Y Kimata; A Tsuru; K Kohno
Journal:  Nat Biotechnol       Date:  2001-08       Impact factor: 54.908

7.  Identification of the cellular receptor for anthrax toxin.

Authors:  K A Bradley; J Mogridge; M Mourez; R J Collier; J A Young
Journal:  Nature       Date:  2001-11-08       Impact factor: 49.962

Review 8.  Understanding the mode of action of diphtheria toxin: a perspective on progress during the 20th century.

Authors:  R J Collier
Journal:  Toxicon       Date:  2001-11       Impact factor: 3.035

9.  Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity.

Authors:  Clare L Bennett; Erwin van Rijn; Steffen Jung; Kayo Inaba; Ralph M Steinman; Martien L Kapsenberg; Björn E Clausen
Journal:  J Cell Biol       Date:  2005-05-16       Impact factor: 10.539

10.  The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18).

Authors:  P Guermonprez; N Khelef; E Blouin; P Rieu; P Ricciardi-Castagnoli; N Guiso; D Ladant; C Leclerc
Journal:  J Exp Med       Date:  2001-05-07       Impact factor: 14.307

View more
  5 in total

1.  Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T-cell production and prophylactic vaccine efficacy.

Authors:  Suzanne Foster; Craig L Duvall; Emily F Crownover; Allan S Hoffman; Patrick S Stayton
Journal:  Bioconjug Chem       Date:  2010-11-02       Impact factor: 4.774

2.  Modular domain swapping among the bacterial cytotoxic necrotizing factor (CNF) family for efficient cargo delivery into mammalian cells.

Authors:  Elizabeth E Haywood; Mengfei Ho; Brenda A Wilson
Journal:  J Biol Chem       Date:  2018-01-25       Impact factor: 5.157

3.  Monitoring the T cell response to genital tract infection.

Authors:  Nadia R Roan; Todd M Gierahn; Darren E Higgins; Michael N Starnbach
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-31       Impact factor: 11.205

4.  Both CD4+ and CD8+ T cells respond to antigens fused to anthrax lethal toxin.

Authors:  Christine A Shaw; Michael N Starnbach
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

5.  CD11c+ cells are required to prevent progression from local acute lung injury to multiple organ failure and death.

Authors:  Jami E Milam; John R Erb-Downward; Gwo-Hsiao Chen; Marcin F Osuchowski; Roderick McDonald; Stephen W Chensue; Galen B Toews; Gary B Huffnagle; Michal A Olszewski
Journal:  Am J Pathol       Date:  2009-11-30       Impact factor: 4.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.